Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
|Articles|January 6, 2022
Daily Medication Pearl: Anifrolumab-fnia (Saphnelo)
Author(s)Saro Arakelians, PharmD
Listen
0:00 / 0:00
Key Takeaways
- Anifrolumab-fnia is indicated for moderate to severe systemic lupus erythematosus in adults receiving standard therapy.
- Administered as a 300 mg intravenous infusion every four weeks, it comes in a single-dose vial.
Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody indicated for the treatment of moderate to severe systemic lupus erythematosus.
Advertisement
Medication Pearl of the Day: Anifrolumab-fnia (Saphnelo)
Indication: Saphnelo is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus, who are receiving standard therapy.
Insight:
- Dosing: The recommended dosage is 300 mg as an intravenous infusion over a 30-minute period every 4 weeks.
- Dosage forms: Injection 300 mg/2 mL (150 mg/mL) in a single-dose vial.
- Adverse events: Most common adverse drug reactions (incidence ≥5%) are nasopharyngitis, upper respiratory tract infections, bronchitis, infusion-related reactions, herpes zoster, and cough.
- Mechanism of action: Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs.
- Manufacturer: AstraZeneca
Sources:
Advertisement
Related to this article
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Novo Nordisk's top-line phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
4
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
5